

# Author Index Volume 16 (2016)

The issue number is given in front of the pagination

- Al Ali, A., see Al-Amri, A.M. (3) 377–383  
Al Ali, R., see Al-Amri, A.M. (3) 377–383  
Al-Amri, A.M., C. Vatte, C. Cyrus, S. Chathoth, T.M. Hashim, Y.S. Mohamed, R. Al Ali, A. Alsaïd and A. Al Ali, Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma (3) 377–383  
Allegra, E., see Trapasso, S. (2) 275–280  
Alsaïd, A., see Al-Amri, A.M. (3) 377–383  
Álvarez, M., see García González, M. (4) 555–557  
Amininia, S., see Eskandari-Nasab, E. (1) 109–115  
An, X., see Lv, Y. (1) 89–97  
Aoki, D., see Nomura, H. (1) 145–152  
Araújo, A.S., I.C. Nogueira, A.G. Neto, I.L. de Medeiros, M.T.A.P. Morano, G.P.F. da Silva, F.A. Santos, M.O. De Moraes Filho and E.D.B. Pereira, The impact of lung cancer resection surgery on fibrinogen and C-reactive protein and their relationship with patients outcomes: A prospective follow up study (1) 47–53  
Aras, G., see Kanmaz, Z.D. (3) 489–498  
Asanuma, K., A. Matsumine, T. Nakamura, T. Matsubara, Y. Asanuma, T. Oi, M. Goto, K. Okuno, T. Kakimoto, Y. Yada and A. Sudo, Impact of plasma fibrinogen levels in benign and malignant soft tissue tumors (3) 453–458  
Asanuma, Y., see Asanuma, K. (3) 453–458  
Asgari, M., see Jahed, M. (4) 627–632  
Assadollahi, Z., see Jafarzadeh, A. (4) 545–554  
Azuma, T., see Saito, M. (1) 171–180  
Bahadır, A., see Kanmaz, Z.D. (3) 489–498  
Bai, C., see Chen, W. (4) 653–664  
Banescu, C., see Loghin, A. (2) 211–217  
Belfiore, A., see Trapasso, S. (2) 275–280  
Benedetti, I., see Reyes, N. (1) 191–202  
Bergis, D., V. Kassis and H.H. Radeke, High plasma sST2 levels in gastric cancer and their association with metastatic disease (1) 117–125  
Bettin, A., see Reyes, N. (1) 191–202  
Blizniak, R., see Lamperska, K.M. (1) 55–64  
Borda, A., see Loghin, A. (2) 211–217  
Cai, H., see Li, X. (1) 11–17  
Camus, M., see Zavala, V. (1) 99–107  
Cao, C., W. Wang and P. Jiang, Clustering of self-organizing map identifies five distinct medulloblastoma subgroups (3) 327–332  
Cao, D., see He, Y.-C. (1) 127–135  
Cao, W., see Zhao, R. (4) 567–574  
Cao, X., see Zhao, R. (4) 567–574  
Cao, Y., see He, Y.-C. (1) 127–135  
Caramés, J., see García González, M. (4) 555–557  
Carvalho, P., see Zavala, V. (1) 99–107  
Chang, Z., see Zhao, R. (4) 567–574  
Chathoth, S., see Al-Amri, A.M. (3) 377–383  
Chen, F., see Chen, W. (4) 653–664  
Chen, G., see Wang, Q. (1) 1–9  
Chen, H.-M., see Fan, N.-J. (2) 235–243  
Chen, H.-Y., see Li, K.-Y. (1) 137–144  
Chen, Q., see Ni, Z. (3) 445–452  
Chen, W., S. Lu, J. Ou, G. Wang, Y. Zu, F. Chen and C. Bai, Metabonomic characteristics and biomarker research of human lung cancer tissues by HR <sup>1</sup>H NMR spectroscopy (4) 653–664  
Chen, W., see Wang, G. (3) 459–465  
Chen, W., see Xie, B.-H. (3) 405–413  
Chen, X., Z. Su, S. Wang and H. Xu, Clinical and prognostic significance of Arl4c expression in colorectal cancer (2) 253–257  
Chen, Y.-M., see Luo, Y.-H. (1) 19–29  
Cheng, J.-Z., see Zhuang, K. (2) 291–300  
Cheng, Z.-H., see Wang, Q. (1) 1–9  
Çermik, T.F., see Kanmaz, Z.D. (3) 489–498  
Chibeleian, C., see Loghin, A. (2) 211–217  
Cui, L., see Wang, G. (3) 459–465  
Cui, L., see Zhao, T. (4) 507–512  
Cui, L., see Zhu, Y. (2) 259–264

- Cybula, M., Ł. Wieteska, M. Józefowicz-Korczyńska, M.S. Karbownik, W.L. Grzelczyk and J. Szemraj, New miRNA expression abnormalities in laryngeal squamous cell carcinoma (4) 559–568
- Cyrus, C., see Al-Amri, A.M. (3) 377–383
- da Cunha Tirapelli, D.P., see Ribeiro, K.B. (4) 513–521
- da Rocha, J.J.R., see Ribeiro, K.B. (4) 513–521
- da Silva Zanetti, J., see Ribeiro, K.B. (4) 513–521
- da Silva, G.P.F., see Araújo, A.S. (1) 47–53
- de Medeiros, I.L., see Araújo, A.S. (1) 47–53
- De Moraes Filho, M.O., see Araújo, A.S. (1) 47–53
- de Oliveira, H.F., see Ribeiro, K.B. (4) 513–521
- DeCotiis, C., Y. Hu, A.K. Greenberg, M. Huie, J.-C.J. Tsay, H. Pass, J.D. Goldberg and W.N. Rom, Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature (2) 219–233
- DeFelice, B.C., see Fahrman, J.F. (4) 609–617
- Demidov, L., see Lyubchenko, L. (1) 153–160
- Deng, M., see Yang, J. (1) 81–88
- Ding, S., see Jiang, Y. (4) 523–528
- Ding, X.-S., see Lv, Y. (1) 89–97
- Dong, C., see Sun, L. (2) 265–273
- Dong, S., see Sun, L. (2) 265–273
- Dong, S., see Wang, Y. (4) 529–536
- Du, X., see Wang, Y. (1) 71–79
- Durczyński, A., see Hogendorf, P. (4) 537–543
- Ebadi, N., see Jahed, M. (4) 627–632
- Ebrahimi, M., see Eskandari-Nasab, E. (1) 109–115
- El-Mesallamy, H.O., see Radwan, S.M. (4) 619–626
- Emelyanova, M., see Lyubchenko, L. (1) 153–160
- Eskandari-Nasab, E., M. Hashemi, M. Ebrahimi and S. Amininia, The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC (1) 109–115
- Fahrman, J.F., D. Grapov, B.C. DeFelice, S. Taylor, K. Kim, K. Kelly, W.R. Wikoff, H. Pass, W.N. Rom, O. Fiehn and S. Miyamoto, Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer (4) 609–617
- Fan, J., see Qin, M. (1) 161–169
- Fan, J., see Zhang, X. (3) 415–423
- Fan, N.-J., H.-M. Chen, W. Song, Z.-Y. Zhang, M.-D. Zhang, L.-Y. Feng and C.-F. Gao, Macrophage mannose receptor 1 and S100A9 were identified as serum diagnostic biomarkers for colorectal cancer through a label-free quantitative proteomic analysis (2) 235–243
- Faryal, R., M. Ishfaq, T. Hayat, I. Mahjabeen and M.A. Kayani, Novel SYK gene variations and changes in binding sites of miRs in breast cancer patients (3) 319–326
- Feizi, M.A.H., see Kazemzadeh, M. (3) 499–505
- Feng, L.-Y., see Fan, N.-J. (2) 235–243
- Feres, O., see Ribeiro, K.B. (4) 513–521
- Fiehn, O., see Fahrman, J.F. (4) 609–617
- Fooladseresht, H., see Jafarzadeh, A. (4) 545–554
- Fu, J., see Wang, G. (3) 459–465
- Fu, J., see Zhu, Y. (2) 259–264
- Gao, C.-F., see Fan, N.-J. (2) 235–243
- Gao, G.Z., see Gu, J.J. (3) 309–317
- Gao, X., see Mao, Y. (3) 351–358
- Gao, X., see Xu, X.F. (3) 467–476
- Gao, Y., see Li, X. (1) 11–17
- Gao, Z.-W., J.-B. Huang, Q. Lin, Q. Qin, Y.-J. Liang, L. Zhou and M. Luo, The effects of PK11195 on meningioma was associated with allopregnanolone biosynthesis, which was mediated by translocator protein 18 Kda (1) 65–69
- García González, M., D. Vela, M. Álvarez and J. Caramés, Inflammatory myofibroblastic duodenal tumor: A rare cause of massive intestinal bleeding (4) 555–557
- Garcia, S.B., see Ribeiro, K.B. (4) 513–521
- Garozzo, A., see Trapasso, S. (2) 275–280
- Ge, Z., see Qin, M. (1) 161–169
- Geliebter, J., see Reyes, N. (1) 191–202
- Ghadakzadeh, S., see Jahed, M. (4) 627–632
- Ghaderi, A., see Jafarzadeh, A. (4) 545–554
- Goldberg, J.D., see DeCotiis, C. (2) 219–233
- Golusinski, P., see Lamperska, K.M. (1) 55–64
- Golusinski, W., see Lamperska, K.M. (1) 55–64
- Gorodkiewicz, E., see Sankiewicz, A. (3) 343–350
- Goto, M., see Asanuma, K. (3) 453–458
- Grapov, D., see Fahrman, J.F. (4) 609–617
- Greenberg, A.K., see DeCotiis, C. (2) 219–233
- Grzelczyk, W.L., see Cybula, M. (4) 559–568
- Gu, J.J., G.Z. Gao and S.M. Zhang, MiR-218 inhibits the tumorigenesis and proliferation of glioma cells by targeting Robo1 (3) 309–317
- Gu, M., see Wang, Q. (1) 1–9
- Gu, X., J.-Q. Xue, S.-J. Han, S.-Y. Qian and W.-H. Zhang, Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer (3) 395–403
- Gündoğan, C., see Kanmaz, Z.D. (3) 489–498
- Guo, L., see Xu, X.F. (3) 467–476
- Guo, M., see Zhang, X. (3) 415–423

- Guszczyk, T., see Sankiewicz, A. (3) 343–350
- Hamdy, N.M., see Radwan, S.M. (4) 619–626
- Han, J., see Zhang, X. (3) 415–423
- Han, S.-J., see Gu, X. (3) 395–403
- Harbron, C., see Nomura, H. (1) 145–152
- Hashemi, M., see Eskandari-Nasab, E. (1) 109–115
- Hashemzadeh, S., see Kazemzadeh, M. (3) 499–505
- Hashim, T.M., see Al-Amri, A.M. (3) 377–383
- Hayat, T., see Faryal, R. (3) 319–326
- He, E., see Wang, Y. (4) 529–536
- He, F., see Sun, L. (2) 265–273
- He, L., see He, Y.-C. (1) 127–135
- He, S., M. Liu, W. Zhang, N. Xu and H. Zhu, Overexpression of p21-activated kinase 7 associates with lymph node metastasis in esophageal squamous cell cancers (2) 203–209
- He, X., see Xie, B.-H. (3) 405–413
- He, Y.-C., Y. Shen, Y. Cao, F.-Q. Tang, D.-F. Tian, C.-F. Huang, H. Tao, F.-L. Zhou, B. Zhang, L. Song, L. He, L.-M. Lin, F.-G. Lu, D.-F. Liao and D. Cao, Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker (1) 127–135
- Hegab, H.M., see Radwan, S.M. (4) 619–626
- Heo, D.S., see Park, S. (3) 425–433
- Hirano, H., see Saito, M. (1) 171–180
- Hishimoto, A., see Saito, M. (1) 171–180
- Hodgson, D., see Nomura, H. (1) 145–152
- Hogendorf, P., A. Durczyński, A. Skulimowski, A. Kumor, G. Poznańska and J. Strzelczyk, Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report (4) 537–543
- Hosseini, S.A., see Jahed, M. (4) 627–632
- Hosseini, S.M., see Najafi, A. (1) 31–45
- Hu, G., see Zhang, X. (3) 415–423
- Hu, X., see Wang, G. (3) 459–465
- Hu, X.C., see Xu, X.F. (3) 467–476
- Hu, Y., see DeCotiis, C. (2) 219–233
- Hua, R.-X., see Xie, B.-H. (3) 405–413
- Huang, C.-F., see He, Y.-C. (1) 127–135
- Huang, J.-B., see Gao, Z.-W. (1) 65–69
- Huang, Q., see Zhang, X. (3) 415–423
- Huang, X., see Li, Z. (4) 633–639
- Huie, M., see DeCotiis, C. (2) 219–233
- Huo, X., see Qin, M. (1) 161–169
- Ishfaq, M., see Faryal, R. (3) 319–326
- Jafarzadeh, A., H. Fooladseresht, M. Nemati, Z. Asadollahi, A. Sheikhi and A. Ghaderi, Higher circulating levels of chemokine CXCL10 in patients with breast cancer: Evaluation of the influences of tumor stage and chemokine gene polymorphism (4) 545–554
- Jahed, M., N. Ebadi, M. Mivehchi, T. Majidzadeh, M. Shahshanipour, M. Asgari, S. Ghadakzadeh and S.A. Hosseini, MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence (4) 627–632
- Jia, H., see Wang, Y. (1) 71–79
- Jia, X.-J., see Li, R.-H. (3) 435–444
- Jiang, H., see Jiang, Y. (4) 523–528
- Jiang, L.-C., see Li, K.-Y. (1) 137–144
- Jiang, P., see Cao, C. (3) 327–332
- Jiang, W., see Zhao, R. (4) 567–574
- Jiang, X., see Wang, Y. (4) 529–536
- Jiang, Y., H. Xu, H. Jiang, S. Ding and T. Zheng, Pre-treatment neutrophil-lymphocyte count ratio may associate with gastric cancer presence (4) 523–528
- Jin, C.-S., see Zhuang, K. (2) 291–300
- Jin, Y., see Zhang, X. (3) 415–423
- Jinno, H., see Nomura, H. (1) 145–152
- Józefowicz-Korczyńska, M., see Cybula, M. (4) 559–568
- Kakimoto, T., see Asanuma, K. (3) 453–458
- Kala, M.V., see Shaikh (3) 301–307
- Kanmaz, Z.D., G. Aras, E. Tuncay, A. Bahadır, C. Kocatürk, Z.A. Yaşar, B. Öz, C.Ü. Özkurt, C. Gündoğan and T.F. Çermik, Contribution of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma (3) 489–498
- Karbownik, M.S., see Cybula, M. (4) 559–568
- Kassis, V., see Bergis, D. (1) 117–125
- Kataoka, F., see Nomura, H. (1) 145–152
- Kayani, M.A., see Faryal, R. (3) 319–326
- Kazemzadeh, M., R. Safaralizadeh, M.A.H. Feizi, R. Ravanbakhsh, M.H. Somi and S. Hashemzadeh, LOC100287225, novel long intergenic non-coding RNA, misregulates in colorectal cancer (3) 499–505
- Keam, B., see Park, S. (3) 425–433
- Kelly, K., see Fahrman, J.F. (4) 609–617
- Kent, M.N., see Mahas, A. (4) 575–597
- Khazaei, S., see Nouraei, N. (3) 367–376
- Kim, D.-W., see Park, S. (3) 425–433
- Kim, K., see Fahrman, J.F. (4) 609–617

- Kim, T.M., see Park, S. (3) 425–433  
 Kim, Y.W., see Park, S. (3) 425–433  
 Kitagawa, Y., see Nomura, H. (1) 145–152  
 Kocatürk, C., see Kanmaz, Z.D. (3) 489–498  
 Kolaković, A., see Petrović, N. (3) 385–394  
 Kolenda, T., see Lamperska, K.M. (1) 55–64  
 Kozłowski, P., see Lamperska, K.M. (1) 55–64  
 Kumor, A., see Hogendorf, P. (4) 537–543
- Lai, Y., see Ni, Z. (3) 445–452  
 Lamperska, K.M., P. Kozłowski, T. Kolenda, A. Tere-  
 siak, R. Blizniak, W. Przybyła, M.M. Masternak,  
 P. Golusinski and W. Golusinski, Unpredictable  
 changes of selected miRNA in expression profile  
 of HNSCC (1) 55–64  
 Lang, Y., see Li, R.-H. (3) 435–444  
 Lee, S.-H., see Park, S. (3) 425–433  
 Lee, Y.-C., see Luo, Y.-H. (1) 19–29  
 Li, A., see Zhao, T. (4) 507–512  
 Li, H.-F., see Li, Y.-F. (4) 641–651  
 Li, H.-P., see Xie, B.-H. (3) 405–413  
 Li, J., see Li, Z. (4) 633–639  
 Li, J., see Wang, Y. (4) 529–536  
 Li, J., see Zhu, Y. (2) 259–264  
 Li, K., see Mao, Y. (3) 351–358  
 Li, K.-Y., J. Zhang, L.-C. Jiang, B. Zhang, C.-P.  
 Xia, K. Xu, H.-Y. Chen, Q.-Z. Yang, S.-W. Liu  
 and H. Zhu, Knockdown of USP39 by lentivirus-  
 mediated RNA interference suppresses the growth  
 of oral squamous cell carcinoma (1) 137–144  
 Li, P., see Li, R.-H. (3) 435–444  
 Li, P., see Li, X. (1) 11–17  
 Li, R., see Yang, J. (1) 81–88  
 Li, R.-H., A.-M. Zhang, S. Li, T.-Y. Li, L.-J. Wang, H.-  
 R. Zhang, P. Li, X.-J. Jia, T. Zhang, X.-Y. Peng,  
 M.-D. Liu, X. Wang, Y. Lang, W.-L. Xue, J. Liu  
 and Y.-Y. Wang, Multiple differential expression  
 networks identify key genes in rectal cancer (3)  
 435–444  
 Li, S., see Li, R.-H. (3) 435–444  
 Li, T.-Y., see Li, R.-H. (3) 435–444  
 Li, X., see Zhao, R. (4) 567–574  
 Li, X., Y. Gao, H. Zhou, W. Xu, P. Li, J. Zhou, T. Xu,  
 B. Yu, Z. Xu, Q. Zou, C. Yin, H. Cai and W. Shen,  
 The relationship between functional promoter -94  
 ins/del ATTG polymorphism in NF- $\kappa$ B1 gene and  
 the risk of urinary cancer (1) 11–17  
 Li, X.-D., see Liu, Q. (2) 281–289  
 Li, Y., see Liu, Q. (2) 281–289  
 Li, Y., see Lv, Y. (1) 89–97  
 Li, Y., X. Liu, J. Zhang and W. Yao, Prognostic role  
 of elevated preoperative systemic inflammatory  
 markers in localized soft tissue sarcoma (3) 333–  
 342  
 Li, Y.-F., P.-Z. Yang and H.-F. Li, Functional polymor-  
 phisms in the *IL-10* gene with susceptibility to  
 esophageal, nasopharyngeal, and oral cancers (4)  
 641–651  
 Li, Z., J. Shu, P. Zhang, W. Sun, B. Yang and  
 H. Zhang, Real-time ultrasensitive VUV-PIMS  
 detection of representative endogenous volatile  
 markers in cancers (3) 477–487  
 Li, Z., see Yang, J. (1) 81–88  
 Li, Z., T. Lv, Y. Liu, X. Huang, Z. Qiu and J. Li, PARP1  
 is a novel independent prognostic factor for the  
 poor prognosis of chordoma (4) 633–639  
 Liang, Y.-J., see Gao, Z.-W. (1) 65–69  
 Liao, D.-F., see He, Y.-C. (1) 127–135  
 Lin, L.-M., see He, Y.-C. (1) 127–135  
 Lin, Q., see Gao, Z.-W. (1) 65–69  
 Liu, G., see Qin, M. (1) 161–169  
 Liu, J., see Li, R.-H. (3) 435–444  
 Liu, L., see Mao, Y. (3) 351–358  
 Liu, L., see Qin, M. (1) 161–169  
 Liu, L.-S., see Xie, B.-H. (3) 405–413  
 Liu, M., see He, S. (2) 203–209  
 Liu, M.-D., see Li, R.-H. (3) 435–444  
 Liu, Q., G.-W. Zhang, Zhu, C.-Y., J.-X. Wei, X. Tian, Y.  
 Li and X.-D. Li, Clinicopathological significance  
 of matrix metalloproteinase 2 protein expression  
 in patients with renal cell carcinoma: A case-  
 control study and meta-analysis (2) 281–289  
 Liu, S.-W., see Li, K.-Y. (1) 137–144  
 Liu, X., see Li, Y. (3) 333–342  
 Liu, Y., see Li, Z. (4) 633–639  
 Loghin, A., C. Banescu, A. Nechifor-Boila, C. Chi-  
 belean, M. Orsolya, A. Nechifor-Boila, F. Tripon,  
 S. Voidazan and A. Borda, *XRCC3* Thr241Met and  
*XPD* Lys751Gln gene polymorphisms and risk of  
 clear cell renal cell carcinoma (2) 211–217  
 Lu, F.-G., see He, Y.-C. (1) 127–135  
 Lu, M., see Mao, Y. (3) 351–358  
 Lu, R.Q., see Xu, X.F. (3) 467–476  
 Lu, S., see Chen, W. (4) 653–664  
 Lukić, S., see Petrović, N. (3) 385–394  
 Luo, M., see Gao, Z.-W. (1) 65–69  
 Luo, X., see Ni, Z. (3) 445–452  
 Luo, Y.-H., P.-C. Tseng, Y.-C. Lee, R.-P. Perng, J.  
 Whang-Peng and Y.-M. Chen, A prospective study  
 of the use of circulating markers as predictors for  
 epidermal growth factor receptor-tyrosine kinase  
 inhibitor treatment in pulmonary adenocarcinoma  
 (1) 19–29

- Lv, P., see Sun, L. (2) 265–273
- Lv, T., see Li, Z. (4) 633–639
- Lv, Y., X.-S. Ding, Y. Li, X. An and L.-Y. Miao, High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients (1) 89–97
- Lv, Z., see Zhang, X. (3) 415–423
- Lyubchenko, L., M. Emelyanova, V. Shamanin, L. Demidov, A. Zasedatelev and T. Nasedkina, The *BRAF* V600E mutation in single-institution study of Russian melanoma patients (1) 153–160
- Ma, H., see Wang, Y. (4) 529–536
- Mahas, A., K. Potluri, M.N. Kent, S. Naik and M. Markey, Copy number variation in archival melanoma biopsies versus benign melanocytic lesions (4) 575–597
- Mahjabeen, I., see Faryal, R. (3) 319–326
- Majidizadeh, T., see Jahed, M. (4) 627–632
- Makhlouf, M.M., Survivin and cyclin E2 genes expression in a cohort of Egyptian acute leukemia patients: Clinical importance and future prospects (1) 181–189
- Malekzadeh, M., see Pakdel, A. (2) 245–252
- Mandušić, V., see Petrović, N. (3) 385–394
- Mao, Y., K. Li, L. Liu, J. Si-tu, M. Lu and X. Gao, Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy (3) 351–358
- Markey, M., see Mahas, A. (4) 575–597
- Masternak, M.M., see Lamperska, K.M. (1) 55–64
- Matsubara, T., see Asanuma, K. (3) 453–458
- Matsumine, A., see Asanuma, K. (3) 453–458
- Mena-Hortelano, R., see Sankiewicz, A. (3) 343–350
- Meng, W., see Sun, L. (2) 265–273
- Meng, X.-W., see Pang, L. (4) 599–607
- Miao, L.-Y., see Lv, Y. (1) 89–97
- Ming, L., see Sun, L. (2) 265–273
- Mivehchi, M., see Jahed, M. (4) 627–632
- Miyamoto, S., see Fahrman, J.F. (4) 609–617
- Mohamed, Y.S., see Al-Amri, A.M. (3) 377–383
- Momose, K., see Saito, M. (1) 171–180
- Morano, M.T.A.P., see Araújo, A.S. (1) 47–53
- Mouri, K., see Saito, M. (1) 171–180
- Mowla, S.J., see Nourae, N. (3) 367–376
- Naghibalhossaini, F., see Pakdel, A. (2) 245–252
- Naik, S., see Mahas, A. (4) 575–597
- Najafi, A., M. Tavallaee and S.M. Hosseini, A systems biology approach for miRNA-mRNA expression patterns analysis in non-small cell lung cancer (1) 31–45
- Nakamura, T., see Asanuma, K. (3) 453–458
- Nasedkina, T., see Lyubchenko, L. (1) 153–160
- Nechifor-Boila, A., see Loghin, A. (2) 211–217
- Nechifor-Boila, A., see Loghin, A. (2) 211–217
- Nemati, M., see Jafarzadeh, A. (4) 545–554
- Neto, A.G., see Araújo, A.S. (1) 47–53
- Ni, Z., Q. Chen, Y. Lai, Z. Wang, L. Sun, X. Luo and X. Wang, Prognostic significance of CLPTM1L expression and its effects on migration and invasion of human lung cancer cells (3) 445–452
- Nivsarkar, M., see Shaikh (3) 301–307
- Nogueira, I.C., see Araújo, A.S. (1) 47–53
- Nomura, H., F. Kataoka, D. Aoki, H. Jinno, Y. Kitagawa, Y. Sato, C. Womack, H. Wombwell, D. Hodgson, M. O'Connell, C. Harbron and X. Yin, Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer (1) 145–152
- Nourae, N., S. Khazaei, M. Vasei, S.F. Razavipour, M. Sadeghizadeh and S.J. Mowla, MicroRNAs contribution in tumor microenvironment of esophageal cancer (3) 367–376
- O'Connor, M., see Nomura, H. (1) 145–152
- Ock, C.-Y., see Park, S. (3) 425–433
- Oi, T., see Asanuma, K. (3) 453–458
- Okuno, K., see Asanuma, K. (3) 453–458
- Orsolya, M., see Loghin, A. (2) 211–217
- Ou, J., see Chen, W. (4) 653–664
- Öz, B., see Kanmaz, Z.D. (3) 489–498
- Özkurt, C.Ü., see Kanmaz, Z.D. (3) 489–498
- Pakdel, A., M. Malekzadeh and F. Naghibalhossaini, The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients (2) 245–252
- Pang, L., D.-W. Wang, N. Zhang, D.-H. Xu and X.-W. Meng, Elevated serum levels of MMP-11 correlate with poor prognosis in colon cancer patients (4) 599–607
- Park, S., S. Park, S.-H. Lee, B. Suh, C.-Y. Ock, B. Keam, T.M. Kim, D.-W. Kim, Y.W. Kim and D.S. Heo, Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer (3) 425–433
- Park, S., see Park, S. (3) 425–433
- Pass, H., see DeCotiis, C. (2) 219–233
- Pass, H., see Fahrman, J.F. (4) 609–617
- Peng, Q., see Wang, Y. (1) 71–79
- Peng, X.-Y., see Li, R.-H. (3) 435–444

- Peng, Y.-B., see Wang, Q. (1) 1–9
- Pereira, E.D.B., see Araújo, A.S. (1) 47–53
- Pérez-Moreno, E., see Zavala, V. (1) 99–107
- Peria, F.M., see Ribeiro, K.B. (4) 513–521
- Perng, R.-P., see Luo, Y.-H. (1) 19–29
- Petrović, N., A. Kolaković, A. Stanković, S. Lukić, A. Šami, M. Živković and V. Mandušić, miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis (3) 385–394
- Potluri, K., see Mahas, A. (4) 575–597
- Poznańska, G., see Hogendorf, P. (4) 537–543
- Przybyła, W., see Lamperska, K.M. (1) 55–64
- Qian, S.-Y., see Gu, X. (3) 395–403
- Qin, M., G. Liu, X. Huo, X. Tao, X. Sun, Z. Ge, J. Yang, J. Fan, L. Liu and W. Qin, Has\_circ\_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma (1) 161–169
- Qin, Q., see Gao, Z.-W. (1) 65–69
- Qin, W., see Qin, M. (1) 161–169
- Qiu, Z., see Li, Z. (4) 633–639
- Radeke, H.H., see Bergis, D. (1) 117–125
- Radwan, S.M., N.M. Hamdy, H.M. Hegab and H.O. El-Mesallamy, Beclin-1 and hypoxia-inducible factor-1 $\alpha$  genes expression: Potential biomarkers in acute leukemia patients (4) 619–626
- Rapatoni, L., see Ribeiro, K.B. (4) 513–521
- Ravanbakhsh, R., see Kazemzadeh, M. (3) 499–505
- Razavipour, S.F., see Nourae, N. (3) 367–376
- Rebollo, J., see Reyes, N. (1) 191–202
- Reyes, N., I. Benedetti, A. Bettin, J. Rebollo and J. Geliebter, The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue (1) 191–202
- Ribeiro, K.B., J. da Silva Zanetti, A. Ribeiro-Silva, L. Rapatoni, H.F. de Oliveira, D.P. da Cunha Tirapelli, S.B. Garcia, O. Feres, J.J.R. da Rocha and F.M. Peria, KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer (4) 513–521
- Ribeiro-Silva, A., see Ribeiro, K.B. (4) 513–521
- Rom, W.N., see DeCotiis, C. (2) 219–233
- Rom, W.N., see Fahrman, J.F. (4) 609–617
- Sadeghizadeh, M., see Nourae, N. (3) 367–376
- Safaralizadeh, R., see Kazemzadeh, M. (3) 499–505
- Saito, M., Y. Yano, H. Hirano, K. Momose, K. Mouri, A. Hishimoto, M. Yoshida and T. Azuma, The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma (1) 171–180
- Šami, A., see Petrović, N. (3) 385–394
- Sankiewicz, A., T. Guszcz, R. Mena-Hortelano, K. Zukowski and E. Gorodkiewicz, Podoplanin serum and urine concentration in transitional bladder cancer (3) 343–350
- Santos, F.A., see Araújo, A.S. (1) 47–53
- Sato, Y., see Nomura, H. (1) 145–152
- Shahshanipour, M., see Jahed, M. (4) 627–632
- Shaikh, M.V. Kala and M. Nivsarkar, CD90 a potential cancer stem cell marker and a therapeutic target (3) 301–307
- Shamanin, V., see Lyubchenko, L. (1) 153–160
- Sheikhi, A., see Jafarzadeh, A. (4) 545–554
- Shen, J., see Wang, Y. (4) 529–536
- Shen, W., see Li, X. (1) 11–17
- Shen, W., see Wang, G. (3) 459–465
- Shen, Y., see He, Y.-C. (1) 127–135
- Shi, H., see Zhang, J. (3) 359–365
- Shu, J., see Li, Z. (3) 477–487
- Si-tu, J., see Mao, Y. (3) 351–358
- Skog, S., see Wang, Y. (4) 529–536
- Skulimowski, A., see Hogendorf, P. (4) 537–543
- Somi, M.H., see Kazemzadeh, M. (3) 499–505
- Song, L., see He, Y.-C. (1) 127–135
- Song, L., see Zhao, R. (4) 567–574
- Song, W., see Fan, N.-J. (2) 235–243
- Stanković, A., see Petrović, N. (3) 385–394
- Strzelczyk, J., see Hogendorf, P. (4) 537–543
- Su, Z., see Chen, X. (2) 253–257
- Sudo, A., see Asanuma, K. (3) 453–458
- Suh, B., see Park, S. (3) 425–433
- Sun, J., see Zhu, Y. (2) 259–264
- Sun, K., see Sun, L. (2) 265–273
- Sun, L., S. Dong, C. Dong, K. Sun, W. Meng, P. Lv, H. Yin, L. Ming and F. He, Predictive value of plasma miRNA-718 for esophageal squamous cell carcinoma (2) 265–273
- Sun, L., see Ni, Z. (3) 445–452
- Sun, S.-Q., see Wang, Q. (1) 1–9
- Sun, W., see Li, Z. (3) 477–487
- Sun, X., see Qin, M. (1) 161–169
- Sun, X.-W., see Wang, Q. (1) 1–9
- Szemraj, J., see Cybula, M. (4) 559–568
- Tan, G.-S., see Xie, B.-H. (3) 405–413
- Tang, F.-Q., see He, Y.-C. (1) 127–135

- Tao, H., see He, Y.-C. (1) 127–135  
 Tao, X., see Qin, M. (1) 161–169  
 Tapia, T., see Zavala, V. (1) 99–107  
 Tavallaei, M., see Najafi, A. (1) 31–45  
 Taylor, S., see Fahrman, J.F. (4) 609–617  
 Teresiak, A., see Lamperska, K.M. (1) 55–64  
 Tian, D.-F., see He, Y.-C. (1) 127–135  
 Tian, X., see Liu, Q. (2) 281–289  
 Trapasso, S., A. Garozzo, A. Belfiore and E. Allegra, Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role (2) 275–280  
 Tripon, F., see Loghin, A. (2) 211–217  
 Tsay, J.-C.J., see DeCotiis, C. (2) 219–233  
 Tseng, P.-C., see Luo, Y.-H. (1) 19–29  
 Tuncay, E., see Kanmaz, Z.D. (3) 489–498
- Vasei, M., see Nouraei, N. (3) 367–376  
 Vatte, C., see Al-Amri, A.M. (3) 377–383  
 Vela, D., see García González, M. (4) 555–557  
 Voidazan, S., see Loghin, A. (2) 211–217
- Wang, D.-W., see Pang, L. (4) 599–607  
 Wang, G., see Chen, W. (4) 653–664  
 Wang, G., see Zhu, Y. (2) 259–264  
 Wang, G., W. Shen, L. Cui, W. Chen, X. Hu and J. Fu, Overexpression of Anillin (ANLN) is correlated with colorectal cancer progression and poor prognosis (3) 459–465  
 Wang, L.-J., see Li, R.-H. (3) 435–444  
 Wang, Q., S. Wang, S.-Q. Sun, Z.-H. Cheng, Y. Zhang, G. Chen, M. Gu, H.-J. Yao, Z. Wang, J. Zhou, Y.-B. Peng, M.-X. Xu, K. Zhang and X.-W. Sun, The effects of RNA interference mediated *VEGF* gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice (1) 1–9  
 Wang, S., see Chen, X. (2) 253–257  
 Wang, S., see Wang, Q. (1) 1–9  
 Wang, W., see Cao, C. (3) 327–332  
 Wang, X., see Li, R.-H. (3) 435–444  
 Wang, X., see Ni, Z. (3) 445–452  
 Wang, X.-N., see Xie, B.-H. (3) 405–413  
 Wang, Y., Q. Peng, H. Jia and X. Du, Prognostic value of hedgehog signaling pathway in digestive system cancers: A systematic review and meta-analysis (1) 71–79  
 Wang, Y., X. Jiang, S. Dong, J. Shen, H. Yu, J. Zhou, J. Li, H. Ma, E. He and S. Skog, Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people (4) 529–536  
 Wang, Y.-Y., see Li, R.-H. (3) 435–444  
 Wang, Z., see Ni, Z. (3) 445–452  
 Wang, Z., see Wang, Q. (1) 1–9  
 Wei, J.-X., see Liu, Q. (2) 281–289  
 Whang-Peng, J., see Luo, Y.-H. (1) 19–29  
 Wieteska, Ł., see Cybula, M. (4) 559–568  
 Wikoff, W.R., see Fahrman, J.F. (4) 609–617  
 Womack, C., see Nomura, H. (1) 145–152  
 Wombwell, H., see Nomura, H. (1) 145–152  
 Wu, F., see Zhang, X. (3) 415–423  
 Wu, Q., see Zhuang, K. (2) 291–300
- Xia, C.-P., see Li, K.-Y. (1) 137–144  
 Xiao, R., see Xu, X.F. (3) 467–476  
 Xiao, X., see Yang, J. (1) 81–88  
 Xie, B.-H., X. He, R.-X. Hua, B. Zhang, G.-S. Tan, S.-Q. Xiong, L.-S. Liu, W. Chen, J.-Y. Yang, X.-N. Wang and H.-P. Li, Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma (3) 405–413  
 Xiong, S.-Q., see Xie, B.-H. (3) 405–413  
 Xu, A., see Zhu, Y. (2) 259–264  
 Xu, D.-H., see Pang, L. (4) 599–607  
 Xu, H., see Chen, X. (2) 253–257  
 Xu, H., see Jiang, Y. (4) 523–528  
 Xu, J., see Zhang, X. (3) 415–423  
 Xu, K., see Li, K.-Y. (1) 137–144  
 Xu, M.-X., see Wang, Q. (1) 1–9  
 Xu, N., see He, S. (2) 203–209  
 Xu, T., see Li, X. (1) 11–17  
 Xu, W., see Li, X. (1) 11–17  
 Xu, X.F., R.Q. Lu, R. Xiao, L. Zhou, X.M. Zhao, X.C. Hu, X. Gao and L. Guo, Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma (3) 467–476  
 Xu, Z., see Li, X. (1) 11–17  
 Xue, J.-Q., see Gu, X. (3) 395–403  
 Xue, M., see Zhang, J. (3) 359–365  
 Xue, W.-L., see Li, R.-H. (3) 435–444
- Yada, Y., see Asanuma, K. (3) 453–458  
 Yang, B., see Li, Z. (3) 477–487  
 Yang, J., see Qin, M. (1) 161–169  
 Yang, J., X. Xiao, R. Li, Z. Li, M. Deng and G. Zhang, Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn- $\beta$  and chemoresistance in acute myeloid leukemia (1) 81–88  
 Yang, J.-Y., see Xie, B.-H. (3) 405–413  
 Yang, L., see Zhang, J. (3) 359–365  
 Yang, P.-Z., see Li, Y.-F. (4) 641–651

- Yang, Q.-Z., see Li, K.-Y. (1) 137–144  
 Yang, Y., see Zhu, Y. (2) 259–264  
 Yano, Y., see Saito, M. (1) 171–180  
 Yao, H.-J., see Wang, Q. (1) 1–9  
 Yao, W., see Li, Y. (3) 333–342  
 Yaşar, Z.A., see Kanmaz, Z.D. (3) 489–498  
 Yin, C., see Li, X. (1) 11–17  
 Yin, H., see Sun, L. (2) 265–273  
 Yin, X., see Nomura, H. (1) 145–152  
 Yoshida, M., see Saito, M. (1) 171–180  
 Yu, B., see Li, X. (1) 11–17  
 Yu, H., see Wang, Y. (4) 529–536  
 Yu, Q., see Zhang, J. (3) 359–365  
 Yuan, H.-J., see Zhuang, K. (2) 291–300
- Zasedatelev, A., see Lyubchenko, L. (1) 153–160  
 Zavala, V., E. Pérez-Moreno, T. Tapia, M. Camus and P. Carvallo, miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival (1) 99–107
- Zhang, A.-M., see Li, R.-H. (3) 435–444  
 Zhang, B., see He, Y.-C. (1) 127–135  
 Zhang, B., see Li, K.-Y. (1) 137–144  
 Zhang, B., see Xie, B.-H. (3) 405–413  
 Zhang, G., see Yang, J. (1) 81–88  
 Zhang, G.-W., see Liu, Q. (2) 281–289  
 Zhang, H., see Li, Z. (3) 477–487  
 Zhang, H.-R., see Li, R.-H. (3) 435–444  
 Zhang, J., H. Shi, M. Xue, Q. Yu, L. Yang, S. Zheng and C. Zhou, An insertion/deletion polymorphism in the *interleukin-1A* 3' untranslated region confers risk for gastric cancer (3) 359–365  
 Zhang, J., see Li, K.-Y. (1) 137–144  
 Zhang, J., see Li, Y. (3) 333–342  
 Zhang, K., see Wang, Q. (1) 1–9  
 Zhang, M.-D., see Fan, N.-J. (2) 235–243  
 Zhang, N., see Pang, L. (4) 599–607  
 Zhang, P., see Li, Z. (3) 477–487  
 Zhang, S.M., see Gu, J.J. (3) 309–317  
 Zhang, T., see Li, R.-H. (3) 435–444  
 Zhang, W., see He, S. (2) 203–209  
 Zhang, W., see Zhao, R. (4) 567–574
- Zhang, W.-H., see Gu, X. (3) 395–403  
 Zhang, X., M. Guo, J. Fan, Z. Lv, Q. Huang, J. Han, F. Wu, G. Hu, J. Xu and Y. Jin, Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis (3) 415–423  
 Zhang, Y., see Wang, Q. (1) 1–9  
 Zhang, Z.-Y., see Fan, N.-J. (2) 235–243  
 Zhao, R., W. Jiang, X. Li, W. Zhang, L. Song, Z. Chang, W. Cao, X. Cao and H. Zong, Anaplastic lymphoma kinase (ALK) gene alteration in gastric signet ring cell carcinoma (4) 567–574  
 Zhao, T., L. Cui and A. Li, The significance of RDW in patients with hepatocellular carcinoma after radical resection (4) 507–512  
 Zhao, X.M., see Xu, X.F. (3) 467–476  
 Zheng, S., see Zhang, J. (3) 359–365  
 Zheng, T., see Jiang, Y. (4) 523–528  
 Zhou, C., see Zhang, J. (3) 359–365  
 Zhou, F.-L., see He, Y.-C. (1) 127–135  
 Zhou, H., see Li, X. (1) 11–17  
 Zhou, J., see Li, X. (1) 11–17  
 Zhou, J., see Wang, Q. (1) 1–9  
 Zhou, J., see Wang, Y. (4) 529–536  
 Zhou, L., see Gao, Z.-W. (1) 65–69  
 Zhou, L., see Xu, X.F. (3) 467–476  
 Zhu, C.-Y., see Liu, Q. (2) 281–289  
 Zhu, H., see He, S. (2) 203–209  
 Zhu, H., see Li, K.-Y. (1) 137–144  
 Zhu, Y., A. Xu, J. Li, J. Fu, G. Wang, Y. Yang, L. Cui and J. Sun, Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer (2) 259–264
- Zhuang, K., Q. Wu, C.-S. Jin, H.-J. Yuan and J.-Z. Cheng, Long non-coding RNA HNF1A-AS is upregulated and promotes cell proliferation and metastasis in nasopharyngeal carcinoma (2) 291–300
- Živković, M., see Petrović, N. (3) 385–394  
 Zong, H., see Zhao, R. (4) 567–574  
 Zou, Q., see Li, X. (1) 11–17  
 Zu, Y., see Chen, W. (4) 653–664  
 Zukowski, K., see Sankiewicz, A. (3) 343–350